Biopharmaceuticals stock Gilead Sciences (NASDAQ: GILD) jumped 2.5% through 12:30 p.m. ET Friday after Needham & Co. upgraded the shares to a buy rating and slapped a $133 price target on the $116 ...
Hosted on MSN
Why Gilead Sciences Stock Just Popped
Needham upgraded Gilead stock to buy today. The analyst sees billion-dollar potential in Gilead's Yeztugo drug for preventing HIV. Gilead stock looked cheap before the upgrade. It could be an even ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results